Methods and intermediates for preparing BTK inhibitors
Patent Information
- Application Number
- JP2019518542
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-10-06
- Filing Date
- 2017-10-05
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2037-10-05
AI Technical Summary
Existing methods for synthesizing chiral hydroxypiperidines, such as those used in the production of Btk inhibitors like ibrutinib, face limitations in yield and selectivity, particularly in achieving high enantiomeric excess (ee) through enzymatic kinetic resolution processes.
An enzymatic kinetic resolution process involving a suitable enzyme and an acyl donor is used to convert racemic compounds of formula (II) to predominantly (S)-enantiomer compounds of formula (I), with the addition of a racemization catalyst, achieving enantiomeric excess greater than 20% and up to 98% ee.
The method significantly enhances the selectivity and conversion to the desired optically active product, producing enantioenriched compounds suitable for further pharmaceutical synthesis, such as ibrutinib, with high ee and efficient yield.
Abstract
Description
[Technology Field]
[0001] The present invention relates to a synthetic procedure and synthetic intermediates for substituted bicyclic compounds, particularly compounds useful as pharmaceuticals, such as Bruton's tyrosine kinase (Btk) inhibitors like ibrutinib. [Background technology]
[0002] Ibrutinib is an organic small molecule with the IUPAC name 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidine-1-yl]piperidine-1-yl]prop-2-en-1-one. It has been described in numerous published documents, including the brochure for International Patent Application Publication No. 2008 / 039218 (Example 1b), and is described as an irreversible inhibitor of Btk.
[0003] Btk plays a crucial role in the B cell signaling pathway, which links surface B cell receptor stimulation to downstream intracellular responses. Btk is a critical regulator of B cell development, activation, signaling, and survival (Kurosaki, Curr Op Imm, 2000, 276-281; Schaeffer and Schwartzberg, Curr Op Imm 2000, 282-288). Furthermore, Btk plays a role in numerous other hematopoietic stem cell signaling pathways, such as macrophage TNF-α production mediated by Toll-like receptors (TLRs) and cytokine receptors, mast cell IgE receptor (FcεRI) signaling, suppression of Fas / APO-1 apoptotic signaling in B lymphocytes, and collagen-stimulated platelet aggregation. For example, see CAJeffries, et al., (2003), Journal of Biological Chemistry 278:26258-26264; NJHorwood, et al., (2003), The Journal of Experimental Medicine 197:1603-1611; Iwaki et al. (2005), Journal of Biological Chemistry 280(48):40261-40270; Vassilev et al. (1999), Journal of Biological Chemistry 274(3):1646-1656 and Quek et al (1998), Current Biology 8(20):1137-1140.
[0004] Ibrutinib is approved in several countries, including the US and EU, for certain hematological malignancies and is also being studied in clinical trials for other hematological malignancies. These malignancies include chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.
[0005] The synthesis of ibrutinib utilizes chiral hydroxypiperidine. It is an object of the present invention to find alternative and / or improved methods for obtaining chiral hydroxypiperidine, and such compounds can be used as intermediates or components in the synthesis of ibrutinib. One method known as a method for preparing chiral hydroxypiperidine is described, for example, in Ju et al, Org. Process Res. Dev., 2014, 18(6), pp827 - 830, in which a biocatalytic process is used and KRED (and NADH / NAD) is used to reduce the corresponding ketone.
[0006] Various strategies can be used for the introduction of chiral centers, including enzymatic strategies. For example, various enzymes can be used (and can be referred to as enzymatic kinetic resolution) to facilitate kinetic resolution. In such a method, considering the conversion of only one enantiomer of the racemate, the maximum theoretical yield is 50%. However, dynamic kinetic resolution can overcome the yield limitation by racemizing the remaining unreacted enantiomer and enable a more complete conversion yield. Many catalysts, such as organometallic catalysts like ruthenium complex catalysts, can play this role, and some of them may be known.
[0007] Furthermore, several documents, such as Hoenig et al, Biocatalysis, 1994, vol9, pp61 - 69 “Enzymatic Resolutions of Heterocyclic Alcohols”, Tatsuya Kikuchi et al, J. Labelled Cpd. Radiopharm. 44, 31 - 41(2001), Lihammar et al, Adv. Synth. Catal. 2011, 353, 2321 - 2317 and Japanese Patent Application Laid - Open No. 2001 - 002637 of patent documents, disclose methods of resolution by enzymes.
[0008] However, such literature only discloses enzymatic processes that result in a specific stereochemistry or configuration of the final product. For example, Hoenig's paper discloses the separation of several heterocyclic alcohols using enzymes. Specifically, the 1-methyl-hydroxy-piperidine ring is first converted to an acetate by transesterification, and then enzymatic hydrolysis proceeds to varying degrees of success. This paper does not disclose enzymatic kinetic acylation. Tatsuya Kikuchi's paper discloses, for example, a Boc-protected hydroxypiperidine that undergoes kinetic resolution mediated by enzymatic acylation with vinyl acetate, where the enzyme is a lipase. Such a reaction proceeds with a specific stereochemistry, namely the (R) configuration of the associated chiral center having the -OAc group. Lihammar's paper also discloses, for example, a 1-N-substituted hydroxy-piperidine that undergoes kinetic resolution under enzymatic conditions in an acylation reaction to form a corresponding compound again having the (R) configuration at the chiral center. Finally, Japanese Patent Publication No. 2001-002637 discloses only an N-substituted pyrrolidine ring with increased enantiomer purity, and further, prepares such optically active compounds from chiral precursors in a stereospecific reaction rather than by an enzymatic kinetic resolution process. [Overview of the project] [Means for solving the problem]
[0009] Enantioenriched form of formula (I) [Formula 1] (In the formula, R 1 represents a hydrogen atom or an acyl group; R 2 represents a hydrogen atom or an amino protecting group; * represents the chiral center of the (S) configuration. A method for preparing the compound, Formula (II) [chemical 2] (In the formula, R 1 represents a hydrogen atom, R 2 (As defined above) A method is provided which involves the enzymatic kinetic resolution of the compound, which is carried out in the presence of an acyl donor, and which may be referred to herein as the method of the present invention (consisting of one or more embodiments). [Modes for carrying out the invention]
[0010] The present invention can be described as a method for preparing a composition comprising a compound of formula (I), which generates an enantioene-rich compound of formula (I) and, instead, the (S)-enantiomer is mainly formed, thus providing more than 20% ee (and, in the embodiments described herein, the ee is even greater).
[0011] The advantages of the present invention, and the differences from those actually disclosed previously, lie in the selectivity of conversion to the desired optically active product and the degree of conversion.
[0012] To avoid any ambiguity, the compound of formula (II) of the starting material is a racemate (or has low enantiopurity, for example, an enantiomeric excess "ee" of less than 20%), i.e., -OR 1 The chiral centers at the binding sites of the groups contain an equimolar mixture of (R)- and (S)- configurations (or the preference of one configuration is substantially lower than that of the other, e.g., less than 60% of the dominant enantiomer). In contrast, the corresponding chiral centers of the compound of formula (I) are primarily (S)- configurations (referred to as "enantioenriched products").
[0013] The method of the present invention is described as enzymatic resolution. Therefore, the method of the present invention is carried out in the presence of a suitable enzyme (which acts on resolution, i.e., selectively reacts with one of the two enantiomers of the racemic mixture of formula (II)). Suitable enzymes may be accompanied by an acyl donor, which are described below.
[0014] In one embodiment, the method of the present invention is dynamic kinetic resolution, in which case the reaction process is further carried out in the presence of a racemization catalyst. For example, any one or more of the following racemization catalysts can be used.
Chemical Formula 3
[0015] Unless otherwise specified, the alkyl groups defined herein may be straight-chain, or branched and / or cyclic if there are a sufficient number (i.e., at least 3) of carbon atoms. Further, if there are a sufficient number (i.e., at least 4) of carbon atoms, such alkyl groups may also be partially cyclic / acyclic. Also, such alkyl groups may be saturated or, if there are a sufficient number (i.e., at least 2) of carbon atoms, unsaturated.
[0016] In the method of the present invention, the R 1 or R 2 portion of the compound of formula (II) does not necessarily have to be the same as the corresponding portion of the compound of formula (I). Thus, the R 1 portion of compound (II) can be a hydrogen atom, but during the process of the method of the present invention, such a group can be converted, for example, to an acyl group (in the compound of formula (I)) if an enzyme is used together with an acyl donor. However, the situation where a compound of formula (I) in which R 1 is acyl is saponified to a further compound of formula (I) in which R 1 is a hydrogen atom is also further encompassed within the scope of the method of the present invention. Similarly, the R 2 portion in the conversion from compound (II) to (I) can be the same (e.g., a protecting group such as tert-butoxycarbonyl (Boc group)) or different. For example, the R 2 nitrogen protecting group of the compound of formula (II) may be necessary during the process of the method of the present invention and thus can be carried over to the resulting compound of formula (I). However, subsequently, the protecting group is removed (i.e., deprotected) so that R 2A compound of formula (I), where is a hydrogen atom, can be obtained. If downstream chemistry is intended (for example, as described below), then in one embodiment, R 2 represents a protecting group (e.g., Boc), and R 2 Compounds of formula (I) where Boc is represented are converted to downstream products, for example, as described below.
[0017] In the method of the present invention, the compound of formula (II) reacts in the presence of an acyl donor (and R 1 Assuming that is a hydrogen atom, such an acyl group would bond to the -OH group during the process, and therefore the -O-acyl moiety (i.e., R 1 This can form a compound of formula (I) representing "acyl" (which, for the purposes of the present invention, is encompassed within the definition of "protecting group" as defined herein). Therefore, R 1 is -C(O)-C 1〜8 Alkyl (where the alkyl portion can be optionally replaced with, for example, halo (e.g., fluoro), -OC) 1〜6 Alkyl (e.g., methoxy; which may optionally be substituted with one or more fluoro atoms) and phenyl (which may optionally be substituted with halo and C atoms) 1〜3 (may be substituted with one or more substituents selected from alkyl) or -C(O)-phenyl (wherein phenyl is optionally substituted with one or more substituents selected from halo and C) 1〜3 (may be substituted with one or more substituents selected from alkyl groups), and R 1 For example, it can form a -C(O)CH2-OCH3 moiety or a -C(O)CH2CH2CH3 moiety (in one embodiment, R 1 The acyl portion represents -C(O)CH2CH2CH3. In one embodiment, the acyl donor is given by the following formula R x -R 1 (In the formula, R 1 As defined above, R x is, -OC 1〜8 Alkyl (optionally, fluoro and -OC) 1〜6The alkyl portion may be substituted with one or more substituents selected from alkyl groups, and the subsequent alkyl portion may optionally be substituted with one or more fluoro atoms), or -O-phenyl (optionally, halo (e.g., chloro, fluoro, bromo), -NO2, C 1〜6 Alkyl and -OC 1〜6 The compound may represent (which may be substituted with one or more substituents selected from alkyl groups, and the latter two alkyl groups themselves may optionally be substituted with one or more fluoro atoms). Possible substituents on the "phenyl" group can be attached to any position (e.g., the para position). In one embodiment, the "acyl donor" is a butyrate ester, for example, R 1 represents -C(O)-CH2CH2CH3 (and therefore the acyl moiety of the compound obtained as a result of formula (I)), and R x The preferred portion (for example, as defined herein) is shown, but in one embodiment it may be optionally substituted with one or more fluoro atoms -OC 1〜6 Alkyl (for example, -OC) 1〜3 This represents an alkyl group and therefore a compound that forms, for example, an -O-CH2-CF3 moiety. Thus, in one embodiment, the acyl donor is 2,2,2-trifluoroethyl butyrate or 4-fluorophenyl butyrate.
[0018] The protecting groups that may be mentioned can be described as follows: Furthermore, R 2 The above shows that it is a nitrogen protecting group. Such groups include - Amides (e.g., N-acetyl) -Optionally substituted N-alkyl (e.g., N-allyl, or optionally substituted N-benzyl) -N-sulfonyl (for example, N-benzenesulfonyl which may be optionally substituted) - Carbamate -urea - Trityl (triphenylmethyl), diphenylmethyl, etc. Examples of things that form it include
[0019] Therefore, R 2 This can represent the following: -C(O)R t1 (In the formula, R t1 is C 1〜6 This may represent an alkyl group, or an aryl group that may be optionally substituted. C 1〜6 Alkyl (the alkyl group may be substituted with one or more substituents selected from optionally substituted aryl groups) (for example, it may form a benzyl moiety); -S(O)2R t2 (In the formula, R t2 (where represents an aryl that may be substituted by choice), or in one embodiment, -C(O)OR t3 (In the formula, R t3 aryl, which may be optionally replaced, or in a further embodiment, C, which may be optionally replaced 1〜6 (For example C 1〜4 ) may represent an alkyl group, for example, tert-butyl (therefore, for example, a tert-butoxycarbonyl protecting group, i.e., when combined with the amino moiety, it forms a tert-butylcarbamate group) or a -CH2 phenyl group (therefore, it forms a carboxybenzyl protecting group); -C(O)N(R t4 )R t5 (In one embodiment, R t4 and R t5 These are, independently, hydrogen atoms, C 1〜6 Alkyl, optionally substituted aryl, or -C(O)R t6 Represents R t6 is C 1〜6 (Represents an alkyl group, or an aryl group which may be optionally substituted.)
[0020] In one embodiment, R 2 is -C(O)OR t3 (In the formula, R t3 is C 1〜6It represents an alkyl group, for example, tert-butyl, and therefore, in one embodiment, R 2 The protecting group is tert-butoxycarbonyl (also known as BOC or Boc group, and referred to as BOC or Boc group herein).
[0021] The method of the present invention produces an enantioen-rich form or product, meaning that the product produced has an enantiomeric excess of more than 20%, e.g., more than 40%, e.g., more than 60%, and in one embodiment, more than 80%. Enantioen-rich products can even exceed 90% (for example, they may consist substantially of a single enantiomer, meaning that the ee may be 95% or more, e.g., more than 98% or about 100%). Such enantioenrichments (or ees) can be obtained directly or by further purification techniques known to those skilled in the art. For example, the method of the present invention is R 1 Compounds of formula (I), where H or an acyl group is represented, can be prepared, and such products are enantioen-rich.
[0022] To avoid any ambiguity, when referring to equivalents, this shall mean molar equivalents.
[0023] In one embodiment, enzymatic kinetic resolution (e.g., dynamic kinetic resolution) is performed in the presence of an enzyme and an acyl donor.
[0024] This enzyme is suitable for yielding a desired split, i.e., for selectively reacting with one of the two enantiomers of the racemic mixture of formula (II) to provide the compound of formula (I) (i.e., an enantioenriched product).
[0025] Enzymes suitable for stereoselective kinetic resolution can be identified using various screening methods. Suitable enzymes can be identified by screening available enzymes, for example, using high-throughput screening techniques or enriched isolation techniques. In such enriched isolation techniques, enrichment substrates can be added to carbon-limited or nitrogen-limited media. Enzymes that yield the best results can be further selected by performing further experiments (e.g., using the conditions described herein and performing the methods of the present invention as described herein). The properties of enzymes can be further enhanced by enzyme engineering. For example, enzyme engineering can be used to improve reaction rate, yield, and reaction selectivity, particularly enantioselectivity. Furthermore, enzyme engineering can be used to broaden the pH and temperature range in which enzymes can be used, as well as their tolerance range to specific solvents. Available enzyme engineering techniques include rational design methods such as site-directed mutagenesis and in vitro directional evolution techniques. Such techniques are described, for example, in KMKoeller and CHWong, “Enzymes for chemical synthesis”, Nature, 409:232-240, and the references cited therein, which are incorporated herein by reference.
[0026] The enzyme can be used in the form of a crude lysate or a purified form. Alternatively, the enzyme can be immobilized and used as is. Immobilization methods are known to those skilled in the art. Useful solid supports include polymer matrices such as calcium alginate, polyacrylamide, Eupergit® and other polymer materials, as well as inorganic matrices such as Celite®. Immobilization methods are advantageous because the enzyme and product can be easily separated. Furthermore, immobilized enzymes can be recycled and reused, making the process more economical. Other methods, such as cross-linked enzyme aggregates (CLEA) or cross-linked enzyme crystals (CLEC), are also applicable to the present invention.
[0027] Specific enzymes found to be suitable for use in the present invention include proteases and lipases. In the method of the present invention, suitable enzymes yielded enantioenriched products of formula (I), for example, products with an ee content of more than 20%.
[0028] The enzyme may be a protease (e.g., a nonspecific protease), such as a serine protease. In one embodiment, it may be a subtilase such as subtilisin (which can be obtained from Bacillus subtilis, or certain types of soil bacteria, such as Bacillus amyloliquefaiens). In one embodiment, the enzyme is a protease that is subtilisin. Subtilisin may also be referred to by several other names, such as alcalase and sabinase, among others (this may depend on the commercial source from which it is obtained). In another embodiment, the enzyme is an alkaline protease such as alkaline protease B. In another embodiment, the enzyme is a lipase derived from papaya (Carica papaya) (or from papayalatex). In another embodiment, the enzyme is papain, which is a protease derived from papayalatex.
[0029] The enzyme may also be a lipase, for example, a lipase expressed and secreted by a pathogen. In one embodiment, the lipase may be lipase A derived from Candida Rugosa, lipase B derived from Candida Rugosa, and / or lipase derived from papaya (Carica Papaya).
[0030] The reaction process can also be carried out in the presence of a phosphate buffer for hydrolysis.
[0031] For example, an enzyme process may be a process in which an enzyme is selected from the following: Savinase (for example, sold by ChiralVision, also known as "SAV") - from the protease group Candida Rugosa Lipase B (e.g., sold by Almac, e.g., catalog numbers AH24 and / or AH09) Candida Rugosa Lipase A (e.g., sold by Almac, e.g., product code AH06) Papaya (Carica papaya) derived lipase (e.g., sold by Almac, e.g., product code AH17) Alkaline protease B (e.g., sold by Almac, e.g., product code AH19) Subtilisin (for example, sold by Almac)
[0032] The use of such enzymes is advantageous to the selectivity of the method of the present invention, and the (S) configuration is mainly produced (favorably for the (R) configuration). Positive ees can be obtained with any of these enzymes, in one embodiment the enzyme is subtilisin or savinase (in particular savinase is sold by ChiralVision; also referred to herein as "SAV").
[0033] Further details regarding specific enzymes from the above-mentioned commercial sources can be obtained from the suppliers. For example, in the case of Savinase from ChiralVision (also known as "Savinase, subtilisin"), this is a protease derived from the Bacillus species with an activity of 750 ELU / g (covalently bonded, e.g., on acrylic beads) (where ELU refers to enzyme-bound immunosorbent units; 1 ELU unit = 1 μmol of lactate (hydrolysis of ethyl lactate) / g released per minute by the immobilized enzyme at 25°C and pH 6.8).
[0034] In the method of the present invention, a suitable amount of enzyme may be used, and this may depend on the specific enzyme selected. However, in one embodiment, the method of the present invention is carried out in the presence of about 1 to 100 g / mol (e.g., about 10 to 50 g / mol, e.g., about 25 g / mol). In one embodiment, these amounts are particularly used when, for example, a Savinase catalyst is used. In this case, "per mole" means per mole of the compound of formula (II).
[0035] In one embodiment, enzymatic kinetic resolution (e.g., dynamic kinetic resolution) is performed in the presence of an enzyme and an acyl donor, the acyl donor being as follows: Acetyl donors (e.g., isopropenyl acetate, phenyl acetate, etc.) Butyrate ester donors (e.g., isopropyl butyrate, 2,2,2-trifluoroethyl butyrate (TFEB), vinyl butyrate, etc.) Selected from. In one embodiment, the acyl donor is a butyrate ester donor, which can advantageously result in improved ee and / or improved yield conversion (in some examples), as demonstrated experimentally, for example.
[0036] The conversion rate (and the ee rate of the desired product) of the method of the present invention may increase depending on the acyl donor used and / or the solvent (or conditions) used. In one embodiment, the conversion rate may be greater than 10%, for example greater than 20%, for example greater than 30% (about 50% in one embodiment, or greater than 50% in a further embodiment), and / or the ee rate may be greater than 30%, for example greater than 50%, for example greater than 70% (greater than 90%, for example greater than 95%, or about 100% in one embodiment).
[0037] In the method of the present invention, at least 1 equivalent of the acyl donor is used with respect to the compound of formula (II). In one embodiment, at least 1.5 equivalents (with respect to the compound of formula (II)) are used. For example, about 2 equivalents (or at least 2 equivalents) are used. In one embodiment, less than 4 equivalents (e.g., less than 3 equivalents) are used, which may have the advantage that the method of the present invention does not result in a decrease (or reduction) of ee.
[0038] Advantageously, when the kinetic reconciliation process of the present invention is carried out in the presence of a savinase enzyme and a butyrate ester acyl donor, the ee can be greater than 50% (e.g., greater than 60%, greater than 75%, greater than 90% in one embodiment, greater than 95%) and / or the conversion rate can be greater than 5% (e.g., greater than 10%, greater than 20%, or greater than 30%, greater than 50% in one embodiment). The highest conversion rate can be obtained when vinyl butyrate is used.
[0039] In one embodiment, the method of the present invention is carried out in the presence of a base such as an organic or inorganic base. Such bases that can be used include carbonate bases (e.g., sodium carbonate, calcium carbonate, barium carbonate, cesium carbonate, potassium carbonate, etc.), hydroxide bases (e.g., potassium hydroxide, lithium hydroxide, magnesium hydroxide, etc.), alkoxide bases (e.g., tert-butoxides such as potassium tert-butoxide), amine bases (e.g., trialkylamines, e.g., triethylamine, dimethylaminopyridine (DMAP), etc.), amide bases (e.g., LDA or LiHMDS, i.e., lithium diisopropylamide or lithium bis(trimethylsilyl)amide), or other suitable bases (or mixtures of bases). In one embodiment, the base used is an inorganic base (e.g., sodium carbonate).
[0040] In one embodiment, at least 0.25 equivalents of base are used for the compound of formula (II) (the base may be one type of base or a mixture of two or more bases, e.g., two different bases). In one embodiment, at least about 0.5 equivalents of base are present (this has the advantage that even such an amount can significantly increase the reaction rate). In one embodiment, about 1, 2, 3, or 4 equivalents of base (for the compound of formula (II)) are used. Using 2 equivalents (or more) of base may result in only a slight increase in conversion rate. Therefore, in one embodiment, about 0.5 to 1.5 (e.g., about 1) equivalents of base (e.g., an inorganic base such as a carbonate, e.g., sodium carbonate) are used. It can be understood that different bases may result in different reaction efficiencies and / or different yields and / or purity of the desired product.
[0041] In one embodiment, the method of the present invention is carried out in the presence of a suitable solvent. Suitable bases include aromatic solvents (e.g., toluene, pyridine), ethers (e.g., dioxane, THF (tetrahydrofuran), ethyl acetate (ethyl acetate), methyl ter-butyl ether, 2-methyltetrahydrofuran), alcohols (e.g., propanol, tert-amyl alcohol), and alkanes (e.g., heptane, cyclohexane). In one embodiment, the solvent is one that yields the highest conversion rate while maintaining a high ee. All of the aforementioned alcohols contributed to ensuring that the product obtained by the method of the present invention (compound of formula (I)) maintains a high ee (more than 90% in one embodiment). In one embodiment, the solvent used in the method of the present invention may be toluene or methyl THF. Such solvents may have the advantage of achieving the fastest conversion (and also maintaining a high ee, as described herein, for example). For example, R 2 Boc is R 1In the reaction of the compound of formula (II) in which is a hydrogen atom, different solvents yield different conversions (and different conversion rates) when Savinase (25 g / mol) is used as the enzyme, DIPEA (1 equivalent relative to the compound of formula (II)) as the base, vinyl butyrate (2 equivalents relative to the compound of formula (II)) as the acyl donor, and the solvent is diluted to 1 L / mol at a reaction temperature of 30°C; in this case, toluene gives a conversion rate of over 20% in 10 hours and a conversion rate of over 50% in 50 hours (R 2 Boc is R 1 The ee was maintained at 94.8% with the desired product of formula (I), which is -C(O)-C3H7); Me-THF, in this case, gave a conversion rate of about 15% at 10 hours and about 40% (but less than 50%) at 50 hours (while maintaining 97.2% ee with the same desired product).
[0042] In the methods of the present invention as performed in examples where a solvent is used, the ratio of solvent per mole of the compound of formula (II) must be reasonable to ensure that the conversion of the compound of formula (II) to the compound of formula (I) is carried out efficiently. For example, a suitable amount of solvent may be about 0.25 L / mol (relative to moles of the compound of formula (II)) to 6 L / mol (e.g., about 0.25 L / mol to 4 L / mol). In one embodiment, about 0.5 L / mol to 1.5 L / mol (e.g., about 1 L / mol) of solvent is used.
[0043] The reaction temperature of the method of the present invention is, in one embodiment, about 0°C to about 60°C, but depends on how the temperature affects the ee of the final product (balanced with the increase in conversion that may occur with increasing temperature). For example, in one embodiment, the temperature is kept below about 50°C because higher temperatures may result in a decrease (or reduction) of ee. In further embodiments, the temperature is kept above room temperature (e.g., above about 25°C) because it may have a positive effect on the reaction rate, particularly the conversion rate. In one embodiment, the method of the present invention is carried out at a temperature of about 25 to 40°C (e.g., about 25 to 35°C), for example, at about 30°C.
[0044] The method of the present invention can also be carried out for a suitable time. For example, the progress of the reaction can be monitored (e.g., by thin-layer chromatography), and the duration may be about 1 hour to about 72 hours. In one embodiment, the reaction time may be about 12 hours to about 48 hours (e.g., about 16 to 48 hours, e.g., 24 to 48 hours, e.g., about 40 hours).
[0045] The result of the method of the present invention is, in essence, a kinetic resolution, the conditions for which it is described herein. If this kinetic resolution is not a dynamic kinetic resolution, undesirable products (e.g., unreacted starting materials) can be removed or separated using standard conditions.
[0046] In a further aspect of the present invention, a method is provided for separating the obtained product (compound of formula (I)) from the method of the present invention (which may be referred to herein as "the compound of the present invention"). Thus, the compound of the present invention (or the product obtained by the method of the present invention) can be separated / isolated. This can be achieved in several ways, such as: - Flash column chromatography - Precipitation / crystallization - Derivatization, followed by optional precipitation / crystallization. - Extraction (e.g., extraction after derivatization) -distillation
[0047] In one embodiment, the method is derivatization, for example, by derivatizing an undesirable product (e.g., unreacted starting material) (e.g., by reacting it with succinic anhydride to form a group having a carboxylic acid moiety at the end), which allows for possible separation, extraction, or isolation (e.g., the carboxylic acid can be removed in a post-treatment step).
[0048] In further embodiments of the present invention, a method of the present invention, as described herein, is provided, which is subsequently followed by further process steps.
[0049] The compound of formula (I) (enantioenriched form) can be used to prepare further compounds, such as pharmaceuticals (or intermediates thereof) useful for treating cancer (e.g., hematological malignancies), and the pharmaceutical may in particular be ibrutinib.
[0050] Ibrutinib is used in the following scheme described in International Publication No. 2008 / 039218 (Example 1b): [C4] It can be prepared according to the following.
[0051] First, 4-amino-3-(4-phenoxyphenyl)-1H-pyrazole[3,4-d]pyrimidine can be prepared by following the procedure described in International Publication No. 2008 / 039218 (which is incorporated herein by reference), for example, by converting 4-phenoxybenzoic acid to the corresponding acyl chloride (using thionyl chloride), and then reacting the resulting product with malononitrile to prepare 1,1-dicyano-2-hydroxy-2-(4-phenoxyphenyl)ethene. The following scheme: [C5] As shown, the methoxy portion is then methylated using trimethylsilyldiazomethane, and the methylation product is treated with hydrazine hydrate to obtain 3-amino-4-cyano-5-(4-phenoxyphenyl)pyrazole, which is then reacted with formamide to obtain 4-amino-3-(4-phenoxyphenyl)-1H-pyrazole[3,4-d]pyrimidine.
[0052] Subsequently, the desired piperidinyl moiety can be introduced to the 1H position of 4-amino-3-(4-phenoxyphenyl)-1H-pyrazole[3,4-d]pyrimidine (i.e., on the -NH moiety of the pyrazole moiety). As shown in the scheme above, this is carried out by the Mitsunobu reaction—more specifically, by converting the hydroxyl moiety of the Boc-protected 3-hydroxypiperidine-1-carboxylate into a better leaving group, thereby causing a substitution reaction with the -NH moiety of the pyrazole (by inversion). Thus, the chirality of hydroxypiperidine is transferred to the product, which is then converted to a single enantiomybrutinib by Boc-deprotection and acylation with acrylic chloride.
[0053] Other transformations (directly or from further products obtained from downstream steps such as those described herein, to the products obtained by the methods of the present invention) can be carried out according to standard methods and processes of the prior art, such as amide formation reactions (in which case the possible conditions and coupling reagents will be known to those skilled in the art), esterification, nucleophilic substitution reactions, and aromatic nucleophilic substitution reactions. [Examples]
[0054] The following examples are intended to illustrate the present invention and should not be construed as limiting the scope of the invention.
[0055] Example 1 General procedure for kinetic partitioning screening [C6] Kinetic reconstitution screening was performed in a 96-well plate on a 0.25 mmol scale. The enzyme (25 g / mol) was weighed and placed in each well with Na2CO3 (1 equivalent; relative to the starting material "compound A"). Then, a stock solution (0.25 mL) containing the corresponding acyl donor (2 equivalents) was added to toluene, followed by the addition of the compound referred to as compound A in scheme A above, R 2 Boc is R 1A stock solution of the compound of formula (II) (i.e., rac-3-hydroxy-N-Boc-piperidine) (0.25 mmol, 0.25 mL), in which the atom is a hydrogen atom, was added. Finally, toluene (0.5 mL) was added to bring the total reaction volume to 1 mL. The well plate was then sealed with a silicone sealing mat and placed on a shaker. The mixture was shaken at 500 rpm and 40°C.
[0056] The sample was collected as follows: 50 μL of the reaction mixture was transferred to another plate, ethyl acetate (0.9 mL) was added, and the plate was centrifuged at 3000 rpm for 15 minutes. An aliquot (0.5 mL) of the supernatant was collected, diluted with ethyl acetate (0.5 mL), and analyzed by chiral gas chromatography ("GC"). Here, the conversion was R 2 Boc is R 1 This refers to a desired compound of formula (I)—referred to as compound B in scheme A above—where is an acyl group as defined herein (and depending on the acyl donor used in the corresponding reaction).
[0057] [Table 1]
[0058] In the table above, to measure ee and conversion rate, ee is based on the ratio of the areas of two possible enantiomers (i.e., in this case, compound B and its enantiomers). The conversion rate is calculated by multiplying the ratio of the sum of the two enantiomers of compound B divided by the sum of the two enantiomers of the starting material compound A by the relative sensitivity coefficient (therefore, in this case, the conversion rate generally refers to the conversion rate from compound A to compound B + its enantiomers).
[0059] General procedure for large-scale reactions: rac-3-hydroxy-N-Boc-piperidine, i.e., compound A (80 mmol, 16.10 g), savinase enzyme (25 g / mol, 2.00 g), and toluene (80 mL) were added to a 100 mL reactor. DIPEA (80 mmol, 16 mL) and vinyl butyrate (1.1 equivalents, 11 mL) were added to the reaction mixture last. The reaction was terminated after 42 hours. The mixture was filtered. The mother liquor was extracted with acidic water (pH < 2, 3 × 100 mL). The organic layer was then dried over MgSO4, filtered, and vacuum concentrated. Flash column chromatography (heptane: Depositphotos, 95% → 90% → 40% heptane) was used (TLC R f "Compound C": 0.7, R f "Compound B (wherein, R 1 (H) is (-C(O)-(CH2)2CH3):0.2, heptane:SiO(7:3). This yielded (S)-"butyrate ester" compound B (3-(S)-butyroxy-N-Boc-piperidine) as a colorless oil (9.29 g, yield 31.7%, ee 97.8%), and (R)-alcohol compound C as a colorless oil (11.06 g, yield 51.0%, ee 61.8%), which were left to solidify.
[0060] Post-treatment modification with succinic anhydride: The general procedure for a large-scale EasySampler reaction was used. The reaction mixture was filtered after 44 hours, and the filtrate was transferred to a clean 100 mL EasyMax reactor. Succinic anhydride (4.80 g, 48 mmol) was added together with 4-dimethylaminopyridine (0.24 g, 2 mmol). The reaction mixture was then heated at 50°C for 18 hours. The mixture was then transferred to a separation funnel, and water (25 mL) and NaHCO3 (saturated, 25 mL) were added to separate the layers. The aqueous layer was extracted twice with toluene (50 mL and 30 mL). The organic layers were combined, extracted with HCl (1 M, 100 mL), and dried over MgSO4. Volatile substances were then removed under vacuum to obtain (S)-"butyrate ester" compound B as a brown liquid (8.056 g, yield 50.1%, ee 97.5%).
[0061] Further Example A: Ibrutinib (or a salt thereof) is prepared by first preparing an intermediate using one of the steps described in Example 1, and then converting ibrutinib (or a salt thereof).
[0062] Further Example B: First, ibrutinib (or a salt thereof) is prepared as in Example 2, and then a pharmaceutical composition is prepared by contacting the ibrutinib (or a salt thereof) thus obtained with a pharmaceutically acceptable carrier, diluent and / or excipient.
Claims
1. Enantioenriched forms of formula (I) [Formula 1] (In the formula, R 1 represents a hydrogen atom or an acyl group; R 2 represents a hydrogen atom or an amino protecting group; * denotes a chiral center in the (S) configuration) 1. A method for preparing a compound of formula (I), comprising: Formula (II) [Case 2] (In the formula, R 1 represents a hydrogen atom, and R 2 is as defined above) the enzymatic kinetic resolution of the compound and the method is carried out in the presence of an acyl donor.
2. The acyl donor is represented by the formula R x -R 1 (In the formula, R 1 is -C(O)-C 1〜8 Alkyl (wherein the alkyl portion is optionally substituted, for example, with halo (e.g., fluoro), -OC 1〜6 Alkyl (e.g., methoxy; itself optionally substituted with one or more fluoro atoms) and phenyl (itself optionally substituted with halo and C 1〜3 alkyl), or —C(O)-phenyl (wherein phenyl is optionally substituted with one or more substituents selected from, for example, halo and C 1〜3 alkyl); R x -OC 1〜8 Alkyl (optionally fluoro and -OC 1〜6 and -O-phenyl (optionally substituted with one or more substituents selected from halo (e.g., chloro, fluoro, bromo), -NO, C 1〜6 Alkyl and -OC 1〜6 alkyl, the latter two alkyl moieties themselves being optionally substituted with one or more fluoro atoms). The method of claim 1, wherein the compound is
3. R 1 is -C(O)-C 1〜6 Alkyl (wherein the alkyl portion is optionally substituted, for example, halo (e.g., fluoro), and -OC 1〜6 3. The method of claim 1 or 2, wherein R represents an alkyl (e.g., methoxy; which itself may optionally be substituted with one or more fluoro atoms).
4. R 1 4. The method of claim 3, wherein represents a -C(O)CH2-OCH3 moiety or a -C(O)CH2CH2CH3 moiety.
5. 4. The method of claim 1, wherein the acyl donor is isopropenyl acetate, trifluoroethyl acetate, vinyl butyrate, isopropyl butyrate, phenyl butyrate (e.g., 3-fluorophenyl butyrate or 4-fluorophenyl butyrate), o-cresol 2-methoxyacetate, or 2,2,2-trifluoroethyl butyrate.
6. 6. The method of claim 5, wherein the acyl donor is 2,2,2-trifluoroethyl butyrate or 4-fluorophenyl butyrate.
7. 7. The process according to claim 1, wherein at least one equivalent of the acyl donor is used relative to the compound of formula (II).
8. 8. The method of claim 7, wherein about 2 equivalents of acyl donor (relative to the compound of formula (II)) are used.
9. 9. The method of claim 1, wherein the enzyme is a protease or lipase (e.g., a serine protease such as subtilisin, alkaline protease B, lipase A from Candida Rugosa, lipase B from Candida Rugosa, and / or lipase from Carica Papaya).
10. 10. The method of claim 9, wherein the enzyme is selected from Savinase, Candida Rugosa lipase B, Candida Rugosa lipase A, Carica Papaya lipase, alkaline protease B and / or subtilisin (e.g., representing Savinase), such as Savinase, AH24, AH06, AH09, AH17, AH19, AH24, and / or subtilisin, which enzymes are available from suppliers such as, but not limited to, Almac and Chiralvision.
11. 11. The process according to any one of claims 1 to 10, carried out in the presence of an inorganic base (e.g. sodium carbonate).
12. 12. The process of any one of claims 1 to 11, carried out in the presence of a suitable solvent (e.g., toluene or methyl THF).
13. 13. The method of any one of claims 1 to 12, carried out at a temperature of about 25 to 40°C (e.g., about 25 to 35°C), for example at about 30°C.
14. 14. The method of any one of claims 1 to 13, wherein the resolution is a dynamic kinetic resolution and is carried out in the presence of a racemization catalyst.
15. The racemization catalyst is [C3] 15. The method of claim 14, wherein the catalyst is one or more selected from the group consisting of:
16. below - Separation / Isolation of Compounds of Formula (I) - Conversion of a compound of formula (I) according to any one of claims 1 to 15 or obtained by the method described above for further separation / isolation to ibrutinib.
16. The method of any one of claims 1 to 15, further comprising a converting step comprising:
17. The following conversion steps to ibrutinib: [C4] 17. The method of claim 16, wherein
18. 18. A pharmaceutical composition comprising ibrutinib (or a salt thereof) obtained according to (i.e. after such process steps) of claim 16 or 17.
19. 19. A method for preparing the pharmaceutical composition of claim 18, comprising:
18. A method comprising the process of preparing ibrutinib (or a salt thereof) as described in claim 16 or 17, followed by contacting it with a pharmaceutically acceptable carrier, diluent and / or excipient.
